TNFRSF9 and follicular lymphoma: Consistent with this hypothesis, patients with follicular lymphoma and other NHLs receiving combination treatment with rituximab and the anti-4-1BB/CD137 mAb utomilumab had a substantially lower incidence of treatment-emergent ADA against utomilumab compared with monotherapy [13, 15].